These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware
(State or other jurisdiction of incorporation or organization) |
94-3207296
(I.R.S. Employer Identification No.) |
|
One Post Street, San Francisco, California
(Address of principal executive offices) |
94104
(Zip Code) |
Large accelerated filer þ | Accelerated filer o |
Non-accelerated filer
o
(Do not check if a smaller reporting company) |
Smaller reporting company o |
Class | Outstanding as of June 30, 2010 | |
Common stock, $0.01 par value | 261,450,777 shares |
Item | Page | |||||||
|
||||||||
|
||||||||
1. Condensed Consolidated Financial Statements
|
||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
6 | ||||||||
18 | ||||||||
28 | ||||||||
28 | ||||||||
|
||||||||
|
||||||||
28 | ||||||||
28 | ||||||||
28 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
30 | ||||||||
EX-10.1 | ||||||||
EX-10.2 | ||||||||
EX-10.3 | ||||||||
EX-10.4 | ||||||||
EX-10.5 | ||||||||
EX-10.6 | ||||||||
EX-10.7 | ||||||||
EX-10.8 | ||||||||
EX-31.1 | ||||||||
EX-31.2 | ||||||||
EX-32 | ||||||||
EX-101 INSTANCE DOCUMENT | ||||||||
EX-101 SCHEMA DOCUMENT | ||||||||
EX-101 CALCULATION LINKBASE DOCUMENT | ||||||||
EX-101 LABELS LINKBASE DOCUMENT | ||||||||
EX-101 PRESENTATION LINKBASE DOCUMENT | ||||||||
EX-101 DEFINITION LINKBASE DOCUMENT |
2
Quarter Ended June 30, | ||||||||
2010 | 2009 | |||||||
Revenues
|
$ | 27,450 | $ | 26,657 | ||||
Cost of Sales
|
26,058 | 25,354 | ||||||
|
||||||||
Gross Profit
|
1,392 | 1,303 | ||||||
Operating Expenses
|
918 | 844 | ||||||
|
||||||||
Operating Income
|
474 | 459 | ||||||
Other Income, Net
|
9 | 10 | ||||||
Interest Expense
|
(43 | ) | (48 | ) | ||||
|
||||||||
Income Before Income Taxes
|
440 | 421 | ||||||
Income Tax Expense
|
(142 | ) | (133 | ) | ||||
|
||||||||
Net Income
|
$ | 298 | $ | 288 | ||||
|
||||||||
|
||||||||
Earnings Per Common Share
|
||||||||
Diluted
|
$ | 1.10 | $ | 1.06 | ||||
Basic
|
$ | 1.12 | $ | 1.07 | ||||
|
||||||||
Dividends Declared Per Common Share
|
$ | 0.18 | $ | 0.12 | ||||
|
||||||||
Weighted Average Common Shares
|
||||||||
Diluted
|
272 | 272 | ||||||
Basic
|
266 | 270 |
3
June 30, | March 31, | |||||||
2010 | 2010 | |||||||
ASSETS
|
||||||||
Current Assets
|
||||||||
Cash and cash equivalents
|
$ | 3,265 | $ | 3,731 | ||||
Receivables, net
|
7,832 | 8,075 | ||||||
Inventories, net
|
9,429 | 9,441 | ||||||
Prepaid expenses and other
|
265 | 257 | ||||||
|
||||||||
Total
|
20,791 | 21,504 | ||||||
|
||||||||
|
||||||||
Property, Plant and Equipment, Net
|
864 | 851 | ||||||
Capitalized Software Held for Sale, Net
|
228 | 234 | ||||||
Goodwill
|
3,522 | 3,568 | ||||||
Intangible Assets, Net
|
522 | 551 | ||||||
Other Assets
|
1,472 | 1,481 | ||||||
|
||||||||
Total Assets
|
$ | 27,399 | $ | 28,189 | ||||
|
||||||||
|
||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current Liabilities
|
||||||||
Drafts and accounts payable
|
$ | 13,296 | $ | 13,255 | ||||
Deferred revenue
|
1,160 | 1,218 | ||||||
Other accrued liabilities
|
2,434 | 2,539 | ||||||
|
||||||||
Total
|
16,890 | 17,012 | ||||||
|
||||||||
|
||||||||
Long-Term Debt
|
2,278 | 2,293 | ||||||
Other Noncurrent Liabilities
|
1,352 | 1,352 | ||||||
|
||||||||
Other Commitments and Contingent Liabilities (Note 10)
|
||||||||
|
||||||||
Stockholders’ Equity
|
||||||||
Preferred stock, $0.01 par value, 100 shares authorized,
no shares issued or outstanding
|
— | — | ||||||
Common stock, $0.01 par value
Shares authorized: June 30, 2010 and March 31, 2010 — 800 Shares issued: June 30, 2010 — 362 and March 31, 2010 — 359 |
4 | 4 | ||||||
Additional Paid-in Capital
|
4,794 | 4,756 | ||||||
Retained Earnings
|
7,488 | 7,236 | ||||||
Accumulated Other Comprehensive Income (Loss)
|
(51 | ) | 6 | |||||
Other
|
(12 | ) | (12 | ) | ||||
Treasury Shares, at Cost, June 30, 2010 — 101 and March 31, 2010 — 88
|
(5,344 | ) | (4,458 | ) | ||||
|
||||||||
Total Stockholders’ Equity
|
6,879 | 7,532 | ||||||
|
||||||||
Total Liabilities and Stockholders’ Equity
|
$ | 27,399 | $ | 28,189 | ||||
|
4
Quarter Ended June 30, | ||||||||
2010 | 2009 | |||||||
Operating Activities
|
||||||||
Net income
|
$ | 298 | $ | 288 | ||||
Adjustments to reconcile to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
120 | 111 | ||||||
Share-based compensation expense
|
33 | 24 | ||||||
Other non-cash items
|
12 | 78 | ||||||
Changes in operating assets and liabilities:
|
||||||||
Receivables
|
172 | 301 | ||||||
Inventories
|
(28 | ) | (42 | ) | ||||
Drafts and accounts payable
|
80 | 356 | ||||||
Deferred revenue
|
(69 | ) | (84 | ) | ||||
Other
|
(90 | ) | (125 | ) | ||||
|
||||||||
Net cash provided by operating activities
|
528 | 907 | ||||||
|
||||||||
|
||||||||
Investing Activities
|
||||||||
Property acquisitions
|
(52 | ) | (42 | ) | ||||
Capitalized software expenditures
|
(35 | ) | (44 | ) | ||||
Other
|
8 | — | ||||||
|
||||||||
Net cash used in investing activities
|
(79 | ) | (86 | ) | ||||
|
||||||||
|
||||||||
Financing Activities
|
||||||||
Common stock repurchases, including shares surrendered for tax
withholding
|
(1,016 | ) | (298 | ) | ||||
Common stock transactions — other
|
144 | 31 | ||||||
Dividends paid
|
(33 | ) | (34 | ) | ||||
Other
|
2 | (2 | ) | |||||
|
||||||||
Net cash used in financing activities
|
(903 | ) | (303 | ) | ||||
|
||||||||
Effect of exchange rate changes on cash and cash equivalents
|
(12 | ) | 17 | |||||
|
||||||||
Net increase (decrease) in cash and cash equivalents
|
(466 | ) | 535 | |||||
Cash and cash equivalents at beginning of period
|
3,731 | 2,109 | ||||||
|
||||||||
Cash and cash equivalents at end of period
|
$ | 3,265 | $ | 2,644 | ||||
|
5
6
7
Quarter Ended June 30, | ||||||||
(In million) | 2010 | 2009 | ||||||
RSUs and RS
(1)
|
$ | 23 | $ | 15 | ||||
PeRSUs
(2)
|
2 | 2 | ||||||
Stock options
|
5 | 4 | ||||||
Employee stock purchase plan
|
3 | 3 | ||||||
|
||||||||
Share-based compensation expense
|
33 | 24 | ||||||
Tax benefit for share-based compensation expense
(3)
|
(11 | ) | (8 | ) | ||||
|
||||||||
Share-based compensation expense, net of tax
|
$ | 22 | $ | 16 | ||||
|
(1) | This expense was primarily the result of PeRSUs awarded in prior years, which converted to RSUs due to the attainment of goals during the applicable years’ performance period. | |
(2) | Represents estimated compensation expense for PeRSUs that are conditional upon attaining performance objectives during the current year’s performance period. | |
(3) | Income tax expense is computed using the tax rates of applicable tax jurisdictions. Additionally, a portion of pre-tax compensation expense is not tax-deductible. |
8
Quarter Ended June 30, | ||||||||
(In millions, except per share amounts) | 2010 | 2009 | ||||||
Net income
|
$ | 298 | $ | 288 | ||||
|
||||||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
266 | 270 | ||||||
Effect of dilutive securities:
|
||||||||
Options to purchase common stock
|
4 | 1 | ||||||
Restricted stock/Restricted stock units
|
2 | 1 | ||||||
|
||||||||
Diluted
|
272 | 272 | ||||||
|
||||||||
|
||||||||
Earnings per common share:
(1)
|
||||||||
Diluted
|
$ | 1.10 | $ | 1.06 | ||||
Basic
|
$ | 1.12 | $ | 1.07 | ||||
|
(1) | Certain computations may reflect rounding adjustments. |
9
Distribution | Technology | |||||||||||
(In millions) | Solutions | Solutions | Total | |||||||||
Balance, March 31, 2010
|
$ | 1,871 | $ | 1,697 | $ | 3,568 | ||||||
Foreign currency translation adjustments and other
|
(34 | ) | (12 | ) | (46 | ) | ||||||
|
||||||||||||
Balance, June 30, 2010
|
$ | 1,837 | $ | 1,685 | $ | 3,522 | ||||||
|
June 30, | March 31, | |||||||
(In millions) | 2010 | 2010 | ||||||
Customer lists
|
$ | 830 | $ | 832 | ||||
Technology
|
189 | 190 | ||||||
Trademarks and other
|
74 | 74 | ||||||
|
||||||||
Gross intangibles
|
1,093 | 1,096 | ||||||
Accumulated amortization
|
(571 | ) | (545 | ) | ||||
|
||||||||
Intangible assets, net
|
$ | 522 | $ | 551 | ||||
|
10
11
Quarter Ended June 30, | ||||||||
(In millions) | 2010 | 2009 | ||||||
Distribution Solutions
|
$ | 7 | $ | — | ||||
Technology Solutions
|
9 | 1 | ||||||
Corporate
|
1 | — | ||||||
|
||||||||
PSIP expense
|
$ | 17 | $ | 1 | ||||
|
||||||||
|
||||||||
Cost of sales
(1)
|
$ | 4 | $ | — | ||||
Operating expenses
|
13 | 1 | ||||||
|
||||||||
PSIP expense
|
$ | 17 | $ | 1 | ||||
|
(1) | Amounts recorded to cost of sales pertain solely to our Technology Solutions segment. |
12
13
14
15
Quarter Ended June 30, | ||||||||
(In millions) | 2010 | 2009 | ||||||
Net income
|
$ | 298 | $ | 288 | ||||
Translation adjustments and other
|
(57 | ) | 95 | |||||
Comprehensive income
|
$ | 241 | $ | 383 | ||||
16
Quarter Ended June 30, | ||||||||
(In millions) | 2010 | 2009 | ||||||
Revenues
|
||||||||
Distribution Solutions
(1)
|
||||||||
Direct distribution & services
|
$ | 18,702 | $ | 17,038 | ||||
Sales to customers’ warehouses
|
4,743 | 6,051 | ||||||
Total U.S. pharmaceutical distribution & services
|
23,445 | 23,089 | ||||||
Canada pharmaceutical distribution & services
|
2,560 | 2,140 | ||||||
Medical-Surgical distribution & services
|
686 | 685 | ||||||
Total Distribution Solutions
|
26,691 | 25,914 | ||||||
Technology Solutions
|
||||||||
Services
|
595 | 589 | ||||||
Software & software systems
|
135 | 130 | ||||||
Hardware
|
29 | 24 | ||||||
Total Technology Solutions
|
759 | 743 | ||||||
Total
|
$ | 27,450 | $ | 26,657 | ||||
Operating profit
(2)
|
||||||||
Distribution Solutions
(3)
|
$ | 505 | $ | 430 | ||||
Technology Solutions
|
64 | 103 | ||||||
Total
|
569 | 533 | ||||||
Corporate
|
(86 | ) | (64 | ) | ||||
Interest Expense
|
(43 | ) | (48 | ) | ||||
Income Before Income Taxes
|
$ | 440 | $ | 421 | ||||
(1) | Revenues derived from services represent less than 1% of this segment’s total revenues for the first quarters of 2011 and 2010. | |
(2) | Operating profit includes net earnings of $3 million and $5 million from equity investments for the first quarters of 2011 and 2010. These earnings are primarily recorded within our Distribution Solutions segment. | |
(3) | Operating profit for the first quarter of 2011 includes $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer. The settlement was recorded as a reduction to cost of sales within our condensed consolidated statements of operations in our Distribution Solutions segment. |
17
Quarter Ended June 30, | ||||||||||||
(In millions, except per share data) | 2010 | 2009 | Change | |||||||||
Revenues
|
$ | 27,450 | $ | 26,657 | 3 | % | ||||||
|
||||||||||||
Income Before Income Taxes
|
$ | 440 | $ | 421 | 5 | |||||||
Income Tax Expense
|
(142 | ) | (133 | ) | 7 | |||||||
Net Income
|
$ | 298 | $ | 288 | 3 | |||||||
|
||||||||||||
Diluted Earnings Per Common Share:
|
$ | 1.10 | $ | 1.06 | 4 | |||||||
Weighted Average Diluted Common Shares
|
272 | 272 | — | |||||||||
18
Revenues: |
Quarter Ended June 30, | ||||||||||||
(In millions) | 2010 | 2009 | Change | |||||||||
Distribution Solutions
|
||||||||||||
Direct distribution & services
|
$ | 18,702 | $ | 17,038 | 10 | % | ||||||
Sales to customers’ warehouses
|
4,743 | 6,051 | (22 | ) | ||||||||
Total U.S. pharmaceutical distribution & services
|
23,445 | 23,089 | 2 | |||||||||
Canada pharmaceutical distribution & services
|
2,560 | 2,140 | 20 | |||||||||
Medical-Surgical distribution & services
|
686 | 685 | — | |||||||||
Total Distribution Solutions
|
26,691 | 25,914 | 3 | |||||||||
|
||||||||||||
Technology Solutions
|
||||||||||||
Services
|
595 | 589 | 1 | |||||||||
Software and software systems
|
135 | 130 | 4 | |||||||||
Hardware
|
29 | 24 | 21 | |||||||||
Total Technology Solutions
|
759 | 743 | 2 | |||||||||
Total Revenues
|
$ | 27,450 | $ | 26,657 | 3 | |||||||
19
Gross Profit: |
Quarter Ended June 30, | ||||||||||||
(Dollars in millions) | 2010 | 2009 | Change | |||||||||
Gross Profit
|
||||||||||||
Distribution Solutions
|
$ | 1,067 | $ | 954 | 12 | % | ||||||
Technology Solutions
|
325 | 349 | (7 | ) | ||||||||
Total
|
$ | 1,392 | $ | 1,303 | 7 | |||||||
|
||||||||||||
Gross Profit Margin
|
||||||||||||
Distribution Solutions
|
4.00 | % | 3.68 | % | 32 | bp | ||||||
Technology Solutions
|
42.82 | 46.97 | (415 | ) | ||||||||
Total
|
5.07 | 4.89 | 18 | |||||||||
20
Quarter Ended June 30, | ||||||||||||
(Dollars in millions) | 2010 | 2009 | Change | |||||||||
Operating Expenses
|
||||||||||||
Distribution Solutions
|
$ | 568 | $ | 531 | 7 | % | ||||||
Technology Solutions
|
262 | 247 | 6 | |||||||||
Corporate
|
88 | 66 | 33 | |||||||||
Total
|
$ | 918 | $ | 844 | 9 | |||||||
Operating Expenses as a Percentage of Revenues
|
||||||||||||
Distribution Solutions
|
2.13 | % | 2.05 | % | 8 | bp | ||||||
Technology Solutions
|
34.52 | 33.24 | 128 | |||||||||
Total
|
3.34 | 3.17 | 17 | |||||||||
|
||||||||||||
Other Income, Net
|
||||||||||||
Distribution Solutions
|
$ | 6 | $ | 7 | (14 | )% | ||||||
Technology Solutions
|
1 | 1 | — | |||||||||
Corporate
|
2 | 2 | — | |||||||||
Total
|
$ | 9 | $ | 10 | (10 | ) | ||||||
21
Quarter Ended June 30, | ||||||||
(In millions) | 2010 | 2009 | ||||||
Distribution Solutions
|
$ | 7 | $ | — | ||||
Technology Solutions
|
9 | 1 | ||||||
Corporate
|
1 | — | ||||||
PSIP expense
|
$ | 17 | $ | 1 | ||||
|
||||||||
Cost of sales
(1)
|
$ | 4 | $ | — | ||||
Operating expenses
|
13 | 1 | ||||||
PSIP expense
|
$ | 17 | $ | 1 | ||||
(1) | Amounts recorded to cost of sales pertain solely to our Technology Solutions segment. |
Quarter Ended June 30, | ||||||||||||
(Dollars in millions) | 2010 | 2009 | Change | |||||||||
Segment Operating Profit
(1)
|
||||||||||||
Distribution Solutions
|
$ | 505 | $ | 430 | 17 | % | ||||||
Technology Solutions
|
64 | 103 | (38 | ) | ||||||||
Subtotal
|
569 | 533 | 7 | |||||||||
Corporate Expenses, Net
|
(86 | ) | (64 | ) | 34 | |||||||
Interest Expense
|
(43 | ) | (48 | ) | (10 | ) | ||||||
Income Before Income Taxes
|
$ | 440 | $ | 421 | 5 | |||||||
|
||||||||||||
Segment Operating Profit Margin
|
||||||||||||
Distribution Solutions
|
1.89 | % | 1.66 | % | 23 | bp | ||||||
Technology Solutions
|
8.43 | 13.86 | (543 | ) | ||||||||
(1) | Segment operating profit includes gross profit, net of operating expenses, plus other income for our two operating segments. |
22
23
24
June 30, | March 31, | |||||||
(Dollars in millions) | 2010 | 2010 | ||||||
Cash and cash equivalents
|
$ | 3,265 | $ | 3,731 | ||||
Working capital
|
3,901 | 4,492 | ||||||
Debt, net of cash and cash equivalents
|
(987 | ) | (1,434 | ) | ||||
Debt to capital ratio
(1)
|
24.9 | % | 23.4 | % | ||||
Net debt to net capital employed
(2)
|
(16.7 | ) | (23.5 | ) | ||||
Return on stockholders’ equity
(3)
|
18.5 | 18.7 | ||||||
(1) | Ratio is computed as total debt divided by total debt and stockholders’ equity. | |
(2) | Ratio is computed as total debt, net of cash and cash equivalents (“net debt”), divided by net debt and stockholders’ equity (“net capital employed”). | |
(3) | Ratio is computed as net income for the last four quarters, divided by a five-quarter average of stockholders’ equity. |
25
26
§ | material adverse resolution of pending legal proceedings; | |
§ | changes in the U.S. healthcare industry and regulatory environment; | |
§ | failure to adequately prepare for and accurately assess the scope, duration or financial impact of public health issues on our operations, whether occurring in the United States or abroad; | |
§ | changes in the Canadian healthcare industry and regulatory environment; | |
§ | competition; | |
§ | the frequency or rate of branded drug price inflation and generic drug price deflation; | |
§ | substantial defaults in payments or a material reduction in purchases by, or loss of, a large customer or group purchasing organization; | |
§ | implementation delay, malfunction or failure of internal information systems; | |
§ | the adequacy of insurance to cover property loss or liability claims; | |
§ | the Company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; | |
§ | loss of third party licenses for technology incorporated into the Company’s products and solutions; | |
§ | the Company’s proprietary products and services may not be adequately protected and its products and solutions may infringe on the rights of others; | |
§ | system errors or failure of our technology products and solutions to conform to specifications; | |
§ | disaster or other event causing interruption of customer access to the data residing in our service centers; | |
§ | increased costs or product delays required to comply with existing and changing regulations applicable to our businesses and products; | |
§ | failure to comply with and changes in government regulations relating to sensitive personal information and to format and data content standards; | |
§ | the delay or extension of our sales or implementation cycles for external software products; | |
§ | changes in circumstances that could impair our goodwill or intangible assets; | |
§ | foreign currency fluctuations or disruptions to our foreign operations; | |
§ | new or revised tax legislation or challenges to our tax positions; | |
§ | the Company’s ability to successfully identify, consummate and integrate strategic acquisitions; | |
§ | changes in accounting principles generally accepted in the United States of America; and | |
§ | general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers. |
27
Item 3. | Quantitative and Qualitative Disclosures about Market Risk |
Item 4. | Controls and Procedures |
Item 1. | Legal Proceedings |
Item 1A. | Risk Factors |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |
Share Repurchases | ||||||||||||||||
Approximate | ||||||||||||||||
Total Number of | Dollar Value of | |||||||||||||||
Shares Purchased | Shares that May | |||||||||||||||
Total Number of | As Part of Publicly | Yet Be Purchased | ||||||||||||||
Shares | Average Price Paid | Announced | Under the | |||||||||||||
(In millions, except price per share) | Purchased | Per Share | Program | Programs (1) | ||||||||||||
April 1, 2010 — April 30, 2010
|
— | $ | — | — | $ | — | ||||||||||
May 1, 2010 — May 31, 2010
|
12.7 | (2) | 68.66 | 12.7 | 531 | |||||||||||
June 1, 2010 — June 30, 2010
|
— | — | — | — | ||||||||||||
|
||||||||||||||||
Total
|
12.7 | 68.66 | 12.7 | 531 | ||||||||||||
(1) | This table does not include shares tendered to satisfy the exercise price in connection with cashless exercises of employee stock options or shares tendered to satisfy tax withholding obligations in connection with employee equity awards. | |
(2) | As a result of our Accelerated Share Repurchase (“ASR”) program, we repurchased 12.7 million shares for $1 billion during the first quarter of 2011. The ASR program was completed on July 26, 2010 and we received 1.9 million additional shares on July 29, 2010. The total number of shares repurchased under the ASR program was 14.6 million shares at an average price per share of $68.66. |
28
Item 3. | Defaults Upon Senior Securities |
Item 4. | Reserved |
Item 5. | Other Information |
Item 6. | Exhibits |
Exhibit | ||
Number | Description | |
10.1*
|
McKesson Corporation Long-Term Incentive Plan, as amended and restated effective May 26, 2010. | |
|
||
10.2*
|
Form of Statement and Terms and Conditions Applicable to Awards Pursuant to the McKesson Corporation Long-Term Incentive Plan, made on or after May 26, 2009. | |
|
||
10.3*
|
McKesson Corporation 2005 Management Incentive Plan, as amended and restated on July 28, 2010. | |
|
||
10.4*
|
McKesson Corporation 2005 Stock Plan, as amended and restated on July 28, 2010. | |
|
||
10.5*
|
Forms of (i) Statement of Terms and Conditions applicable to Options, Restricted Stock, Restricted Stock Units and Performance Shares, (ii) Stock Option Grant Notice and (iii) Restricted Stock Unit Grant Notice, under the McKesson Corporation 2005 Stock Plan, as amended and restated on April 20, 2010. | |
|
||
10.6
|
Third Amended and Restated Receivables Purchase Agreement, dated as of May 19, 2010, among the Company, as servicer, CGSF Funding Corporation, as seller, the several conduit purchasers from time to time party to the Agreement, the several committed purchasers from time to time party to the Agreement, the several managing agents from time to time party to the Agreement, and JPMorgan Chase Bank, N.A., as collateral agent. | |
|
||
10.7††
|
Purchase Agreement, dated as of December 31, 2002, between McKesson Capital Corp. and General Electric Capital Corporation. | |
|
||
10.8††
|
Services Agreement, dated as of December 31, 2002, between McKesson Capital Corp. and General Electric Capital Corporation. | |
|
||
31.1
|
Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
|
||
31.2
|
Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
|
||
32†
|
Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
|
||
101†
|
The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) related notes. |
* | Management contract or compensation plan or arrangement in which directors and/or executive officers are eligible to participate. | |
† | Furnished herewith. | |
†† | Confidential treatment has been requested for certain portions of this exhibit and such confidential portions have been filed with the Securities and Exchange Commission. |
29
McKesson Corporation
|
||||
Dated: July 30, 2010 | /s/ Jeffrey C. Campbell | |||
Jeffrey C. Campbell | ||||
Executive Vice President and Chief Financial Officer | ||||
/s/ Nigel A. Rees | ||||
Nigel A. Rees | ||||
Vice President and Controller | ||||
30
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
Quest Diagnostics Incorporated | DGX |
Suppliers
Supplier name | Ticker |
---|---|
3M Company | MMM |
Gilead Sciences, Inc. | GILD |
Exxon Mobil Corporation | XOM |
Illinois Tool Works Inc. | ITW |
Boston Scientific Corporation | BSX |
Stryker Corporation | SYK |
Dow Inc. | DOW |
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|